Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D016158:Genes, p53 / Q000187:drug effects; D015316:Genetic Therapy; D006801:Humans; D010455:Peptides / Q000627:therapeutic use*; D010534:Peritoneal Neoplasms / Q000473:pathology / Q000628:therapy*; D011499:Protein Processing, Post-Translational; D015533:Transcriptional Activation; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*
D000970:Antineoplastic Agents; D010455:Peptides; D016159:Tumor Suppressor Protein p53; C487567:retro-inverso-TATp53C' peptide